Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A promoter methylation was associated with tumor grade (grade 3-4 vs 1-2: OR 2.31, 95% CI 1.12-4.77, P = 0.023), lymph node metastasis (yes vs no: OR 2.97, 95% CI 1.60-5.52, P = 0.001), tumor histology (squamous cell carcinoma vs adenocarcinoma: OR 0.49, 95% CI 0.22-1.08, P = 0.076), and HPV infection (positive vs negative: OR 0.45, 95% CI 0.28-0.73, P = 0.001).
|
29288321 |
2018 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The expression of all three TSGs were significantly different between NSCLC subtypes: RASSF1A and FUS1 expression levels were significantly lower in squamous cell carcinoma (SCC), and NPRL2/G21 in adenocarcinoma (AC).
|
26112163 |
2015 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Patients with RASSF1A hypermethylation showed significantly longer disease-free survival (P = 0.015) and overall survival periods (P = 0.009) in ADC patients.
|
26222671 |
2015 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In SH, CpG island methylation frequencies of p16(INK4a) (0.0%) and RASSF1A (12.5%) were significantly lower than those in adenocarcinoma (29.4% and 38.2%, respectively); the frequencies of HOX D9, D11, and D13 gene methylation in SH were 37.5%, 33.3%, and 33.3%, respectively.
|
21649526 |
2011 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Conversely, there was a trend toward a higher frequency of RASSF1A methylation in ADC than SCC.
|
21507233 |
2011 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Deregulation of RASSF1A correlated with tumor progression of squamous cell (P = 0.196) and adenocarcinomas (P < 0.05).
|
20193080 |
2010 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Promoter methylation of RASSF1A was detected in 25 of 45 adenocarcinomas and 18 of 46 SCC.
|
21102258 |
2010 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
45% of adenocarcinoma tumors showed RASSF1A promoter methylation in comparison to 17% of squamous cell carcinomas and 22% of large cell carcinomas.
|
19926549 |
2009 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A set of 4 genes, including CDH1 (E-cadherin), SFN (stratifin), RARB (retinoic acid receptor, beta) and RASSF1A (Ras association (RalGDS/AF-6) domain family 1), had their methylation patterns evaluated by MSP (Methylation-Specific Polymerase Chain Reaction) analysis in 49 fresh urinary bladder carcinoma tissues (including 14 cases paired with adjacent normal bladder epithelium, 3 squamous cell carcinomas and 2 adenocarcinomas) and 24 cell sediment samples from bladder washings of patients classified as cancer-free by cytological analysis (control group).
|
18702824 |
2008 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
|
18494062 |
2008 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
By interbreeding isoform specific Rassf1a knockout mice with Apc(+/Min) mice, we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing mice and decreased overall survival.
|
18391979 |
2008 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Reduction or loss of RASSF1A expression was observed in most methylated adenocarcinomas.
|
18182852 |
2007 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In conclusion, the hypermethylation of RASSF1A or RUNX3 gene is therefore a useful biomarker to predict the prognosis in NSCLC, particularly RASSF1A due to SCCs and RUNX3 due to ACs.
|
17606310 |
2007 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
The methylation status of BLU and RASSF1A, as well as the HPV infection status, were assessed in a full spectrum of cervical neoplasia, including 45 low-grade squamous intraepithelial lesions (LSIL), 63 high-grade squamous intraepithelial lesions (HSIL), 107 squamous cell carcinomas (SCC), 23 adenocarcinomas (AC), and 44 normal control tissues.
|
17097722 |
2007 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
The frequency of KRAS mutation and RASSF1A methylation were significantly different between adenocarcinomas (P<0.001) and squamous cell carcinomas (P<0.001).
|
17360030 |
2007 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
LHGDN |
We identified thirteen loci showing significant differential DNA methylation levels between tumor and non-tumor lung; eight of these show highly significant hypermethylation in adenocarcinoma: CDH13, CDKN2A EX2, CDX2, HOXA1, OPCML, RASSF1, SFPR1, and TWIST1 (p-value < 0.0001).
|
17967182 |
2007 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
The frequency of KRAS mutation and RASSF1A methylation were significantly different between adenocarcinomas (P<0.001) and squamous cell carcinomas (P<0.001).
|
17360030 |
2007 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).
|
15639718 |
2005 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Comparison of methylation in adenocarcinoma cell lines and tumors versus non-tumor lung tissue showed methylation of ESR1, PGR1 and RASSF1 to be significantly elevated in adenocarcinoma, with RASSF1 being most significant (P=0.0002).
|
15639718 |
2005 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
LHGDN |
These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inactivation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas.
|
14511407 |
2004 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
RASSF1A methylation was more frequently observed in adenocarcinomas (28 of 72, 39%) than in squamous cell carcinomas (6 of 45, 13%, P = 0.0033).
|
15541815 |
2004 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
These results showed that the majority of the primary NSCLCs with Kras2 mutations lack RASSF1A inactivation, and both RASSF1A inactivation and Kras2 mutation events occur frequently in adenocarcinomas and large cell carcinomas.
|
14511407 |
2004 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Pancreatic adenocarcinomas with K-ras mutation have significantly less RASSF1A methylation and vice versa (P=0.001, chi(2) test).
|
12802288 |
2003 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Our results suggest that epigenetic silencing of RASSF1A may play a role in the development of AC of the uterine cervix.
|
12912945 |
2003 |
Adenocarcinoma
|
0.400 |
PosttranslationalModification
|
group |
BEFREE |
Hypermethylation of RASSF1A was detected in 30% of SCC, 12% of AC and in 1 of the 4 cancer cell lines but was absent in all normal cases.
|
12673680 |
2003 |